05:58 PM EDT, 05/30/2024 (MT Newswires) -- Gilead Sciences ( GILD ) said Thursday its late-stage study of Trodelvy in locally advanced or metastatic urothelial cancer didn't meet its primary endpoint of overall survival in the intention-to-treat population.

A numerical improvement in overall survival favoring Trodelvy was observed, and trends in improvement for select pre-specified subgroups and secondary endpoints of progression-free survival and overall response rate were also shown, Gilead said.

Gilead said it will discuss the results and next steps with regulators.

Price: 61.98, Change: -2.10, Percent Change: -3.28